ABSTRACT OKY 046, a specific thromboxane synthase inhibitor, was used to investigate whether large pulmonary emboli, like microemboli, cause an increase in thromboxane A2 and an associated increase in vascular permeability in sheep. Nineteen sheep were anaesthetised and had cannulas inserted into the afferent lymphatic of the caudal mediastinal lymph node and pulmonary and carotid arteries. Several days later the animals were pretreated with placebo or OKY 046 0 4 mg/kg one hour before being given clotted blood 0-5 g/kg intravenously. After embolisation in the control animals mean pulmonary artery pressure (MPAP) rose from 12 to 34 mm Hg and pulmonary artery wedge pressure (PAWP) fell from 4-4 to 1*5 mm Hg; the cardiac index did not change but the physiological shunt ((sS/T) rose from 17% to 50%. One hour after embolisation the platelet count fell from 76 to 32 x 106/1 whereas at 15 minutes thromboxane B2 rose from 116 to 560 pg/ml in plasma and from 324 to 795 pg/ml in lymph (p < 0-05). By 2 hours the concentration of thromboxane B2 was higher in lymph than in plasma. Lymph flow rose from 8-7 to a maximum of 27 3 ml/h at 15 minutes but despite the increase in flow the lymph:plasma (L:P) protein ratio did not fall, indicating an increased permeability of the blood vessels to protein. Pretreatment with OKY 046 inhibited the rise in plasma and lymph thromboxane B2, and limited the rise of 4S/QT. The changes in MPAP, PAWP, cardiac index, platelet count, lymph flow, and L:P protein ratio, however, were no different from those in untreated sheep. These results indicate that a large pulmonary embolus leads to an increase in plasma and lung lymph thromboxane A2, which moderates the rise in sS/OT in part but not the increase in vascular permeability.
moderates the rise in sS/OT in part but not the increase in vascular permeability.
Several reports have documented an increase in microvascular permeability in the lungs after the intravenous infusion of various microemboli,' such as glass beads, air bubbles, barium sulphate, and platelets.24 The mechanism of the increase in permeability has been related to the activity of white blood cells5 and to thromboxane A26: leucopenia prevented the increase in permeability after air embolism,5 and inhibition of thromboxane synthase prevented the increase in permeability after thrombin infusion.6 A large pulmonary embolus causes platelet entrapment in the lungs and a rise in plasma thromboxane B2, events similar to those accompanying microembolism produced by a thrombin infusion.
This study tests the effect of a specific thromboxane synthesis inhibitor, OKY 046, on microvascular permeability and haemodynamic changes after the injection of large blood clots intravenously into sheep.
Methods
Experiments were conducted in 19 sheep weighing 39-45 kg. Animals were anaesthetised to allow cannulas to be inserted several days before pulmonary embolisation to avoid the effects of surgical trauma and anaesthesia at the time of embolisation. A cannula was inserted into the lymphatic channel draining into the caudal Effect of thromboxane synthase inhibitor on lung vascular permeability after pulmonary embolism in sheep 677 mediastinal lymph node by the technique described by Staub,7 a 14 gauge catheter was inserted into the jugular vein, a 7 French thermistor tipped catheter into the pulmonary artery (Instrumentation Laboratory, Lexington, Montana, USA), and a 20 gauge catheter into the carotid artery. On the day of the study 40 ml blood was withdrawn and 10 units thrombin/ml blood added. The clot was allowed to retract and after two hours the serum was decanted. The clot was cut into 3-5 mm cubes before intravenous infusion.
Measurements were conducted in awake sheep. Lymph was collected directly into a syringe from the cannula on the chest wall. A two hour collection was used to give a baseline lymph flow and protein ratio before embolisation. Measurements were taken at intervals up to four hours after embolisation. Strain gauge transducers (Bentley Laboratories, Irvine, California) were used to monitor the following pressures: mean pulmonary artery pressure, mean pulmonary artery wedge pressure, and mean arterial pressure. Blood was collected in plastic syringes containing ethylene diamine tetra-acetic acid anticoagulant and aspirin, the later in a final concentration of 50 gg/ml. Plasma was immediately separated by centrifugation at 4°C, and then frozen at -20°C for subsequent assay of thromboxane B2 and 6-keto-prostaglandin Fl, (PGF,,). Aliquots of lymph were frozen for later prostanoid assay. All samples of plasma and lymph were coded and analysed blind. Radioimmunoassay for thromboxane B2 and 6-keto-PGF1., the stable hydrolysis products of thromboxane A2 and prostacyclin respectively, were conducted with an antibody supplied by Dr L Levine, Brandeis University, as reported elsewhere.9 The protein content of plasma and lymph was measured and the lymph: plasma protein ratio calculated.'0 Circulating platelet and white blood cell counts were measured by phase microscopy.
After baseline measurements animals were divided randomly and nine received saline placebo and 10 the imidazole derivative OKY 046 (kindly supplied by Ono Pharmaceutica, Osaka, Japan). This specific thromboxane synthase inhibitor was given in a dose of 0 4 mg/kg. One hour later a clot was introduced into the jugular venous catheter. At the end of the experiment all animals were anesthetised and killed.
Statistical analysis to compare treated and control animals used analysis of variance and paired and non-paired t tests. The observation that pulmonary embolism led to a twofold to threefold increase in lymph flow without a fall in the lymph-piasma protein ratio indicates an increase in the permeability of the vascular bed to fluids and proteins. An increase in hydrostatic pressures caused by partial vascular obstruction will induce an increase in fluid flow to the interstitium, but without a parallel increase in protein, so as the L;P protein ratio will fall.'2 The rise in thromboxane B2 levels was not causally related to the increase in permeability since lymph flow and the lymph-plasma protein ratio were not altered when the synthesis of thromboxane A2 was inhibited (fig 4) . In other In summary, pulmonary embolism leads to an increase in microvascular permeability, which appears not to depend solely on thromboxane A2 synthesis and mediation. This is in contrast to thrombin induced -microembolisation, where the increase in permeability _can be prevented by 
